Literature DB >> 36828

Beta-adrenoceptor blocking drugs in hypertension.

A Scriabine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 36828     DOI： 10.1146/annurev.pa.19.040179.001413

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN： 0362-1642            Impact factor:   13.820


× No keyword cloud information.
  9 in total

1.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Role of central beta-adrenoceptors in the control of pentylenetetrazol-induced convulsions in rats.

Authors:  W J Louis; J Papanicolaou; R J Summers; F J Vajda
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

3.  Effect of intracisternal 5,-7-dihydroxytryptamine on the acute antihypertensive action of propranolol in the sino-aortic denervated anaesthetized dog.

Authors:  J L Montastruc; P Montastruc
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

4.  Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension.

Authors:  J Burton; R J Cody; J A Herd; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

5.  Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".

Authors:  O E Brodde; A Daul; N Stuka; N O'Hara; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

6.  Effect of thyroid status on beta-adrenoceptors and calcium channels in rat cardiac and vascular tissue.

Authors:  M H Hawthorn; P Gengo; X Y Wei; A Rutledge; J F Moran; S Gallant; D J Triggle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

7.  Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.

Authors:  D Cambridge; M V Whiting; G Allan
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

8.  Chronic beta 1-adrenoceptor antagonist treatment sensitizes beta 2-adrenoceptors, but desensitizes M2-muscarinic receptors in the human right atrium.

Authors:  S Motomura; N M Deighton; H R Zerkowski; N Doetsch; M C Michel; O E Brodde
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

9.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.